Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 4Takayasu Arteritis 1Skin Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Inflammation 1Hematologic Neoplasms 1Fatigue 1Drug-Related Side Effects and Adverse Reactions 1Depressive Disorder, Major 1Depression 1Colitis 1Cognitive Dysfunction 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Breast Neoplasms 1Breast Carcinoma In Situ 1Anorexia 1Anemia 1

Interventions

Psilocybin 6Therapeutics 2Ketamine 2Exercise 2Venlafaxine Hydrochloride 1Vegetables 1Terminal Care 1Self-Management 1SLI381 1Psychotherapy 1Psychosocial Intervention 1Psychiatric Rehabilitation 1Professional Autonomy 1Niacin 1Mirtazapine 1Minocycline 1Methylphenidate 1Mental Status and Dementia Tests 1Melatonin 1Medical Marijuana 1Interpersonal Psychotherapy 1Injections 1Infliximab 1Gemcitabine 1Fruit 1Fluoxetine 1Ethanol 1Doxorubicin 1Donepezil 1Dignity Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Depression × Infliximab × Clear all
NCT06136546 2025-05-07

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Massachusetts General Hospital

Phase 2 Recruiting
100 enrolled

Depression, Depressive Disorder, Major, Inflammation, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡